<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884153</url>
  </required_header>
  <id_info>
    <org_study_id>CASTRO-B</org_study_id>
    <nct_id>NCT03884153</nct_id>
  </id_info>
  <brief_title>CASTRO-B - Study on CRP Apheresis in STROke Patients in Berlin</brief_title>
  <acronym>CASTRO-B</acronym>
  <official_title>Selective Depletion of C-reactive Protein (CRP) With Therapeutic Apheresis (CRP Apheresis) in Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Nephrology and Internal Intensive Care Medicine, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the use of CRP level reduction in patients after suffering from acute
      ischemic stroke. Using selective CRP-apheresis, the investigators aim to reduce the secondary
      inflammatory tissue damage in the course of infarction maturation using infarction growth in
      MRI as the primary outcome as a surrogate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      C-reactive protein (CRP) is an acute-phase protein binding to phosphocholine, thereby marking
      damaged tissue. This in turn activates the complement system and the cellular immune system
      engaging the unspecific immune system in an inflammatory tissue-degrading reaction. Such a
      pattern is observed in ischemic stroke, and elevated CRP levels can be measured in stroke
      survivors' sera. Several observational studies reproduced higher CRP levels with negative
      outcome in stroke. In another vascular model disease, myocardial infarction, selective CRP
      apheresis reduced infarct size in humans. The investigators therefore designed this pilot
      study to explore the effects of selective CRP reduction in ischemic stroke patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Comparisons will be drawn from historic controls from previous observational stroke studies</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct growth</measure>
    <time_frame>5 ± 1 days after infarction</time_frame>
    <description>Infarct growth measured via DWI-FLAIR volume change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct growth</measure>
    <time_frame>90 ± 14 days after infarction</time_frame>
    <description>Infarct growth measured via diffusion-weighted imaging (DWI)-FLAIR volume change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Severity</measure>
    <time_frame>5 ± 1 days after infarction</time_frame>
    <description>National Institute of Health Stroke Scale (NIHSS) score - ranging from 0-42 - higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome</measure>
    <time_frame>90 ± 14 days after infarction</time_frame>
    <description>Modified ranking scale (mRS) score - ranging from 0-6 with higher scores signifying worse outcome no subscales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dependency</measure>
    <time_frame>90 ± 14 days after infarction</time_frame>
    <description>Barthel Index (BI) - ranging from 0-100 with higher scores signifying better outcome; no subscales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>90 ± 14 days after infarction</time_frame>
    <description>Montreal Cognitive Assessment (MoCA) - ranging from 0-30 with higher scores signifying better outcome; no subscales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life after Stroke via Stroke Impact Scale (SIS)</measure>
    <time_frame>90 ± 14 days after infarction</time_frame>
    <description>Stroke Impact Scale - Stroke Impact Scale (SIS) - measures different aspects of the overall impact of stroke on the patients' health and quality of life with different subscales addressing different domains:
physical problems
memory and thinking
mood and emotions
communication
daily activities
mobility
motor impairment hand
participation
overall recovery higher values represent better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Complications</measure>
    <time_frame>90 ± 14 days after infarction</time_frame>
    <description>Composite frequency of Complications within the time frame</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>CRP apheresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRP apheresis by means of selective apheresis using the &quot;PentraSorb&quot;-CRP adsorber</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRP apheresis</intervention_name>
    <description>selective CRP apheresis by use of the &quot;PentraSorb&quot;-CRP</description>
    <arm_group_label>CRP apheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 85 years

          -  Informed consent signed by patient

          -  Patients with acute ischemic stroke in the Arteria cerebri media (MCA) territory
             within 36 hours of event

          -  Acute MRI with evidence of infarction

          -  NIHSS ≥ 4

          -  CRP &gt; 5 mg/l

        Exclusion Criteria:

          -  Withdrawal of consent

          -  Systolic blood pressure &lt;100 mmHg before the apheresis

          -  Blood pressure relevant extra- and intracranial stenoses (NASCET 70)

          -  Apheresis contraindication

          -  Participation in other interventional studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Meisel, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Hotter, Dr. med.</last_name>
    <phone>+49 30 450 639729</phone>
    <email>benjamin.hotter@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Meisel, Prof. Dr. med.</last_name>
    <phone>+49 30 450 560026</phone>
    <email>andreas.meisel@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NeuroCure Clinical Research Center (NCRC), Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Meisel</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>CRP apheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

